Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics

Ionis Pharmaceuticals, Inc. (IONS)

Today's Latest Price: $62.09 USD

1.65 (2.73%)

Updated Jul 10 6:55pm

Add IONS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IONS Stock Summary

  • The price/operating cash flow metric for Ionis Pharmaceuticals Inc is higher than 90.52% of stocks in our set with a positive cash flow.
  • IONS's price/sales ratio is 9.02; that's higher than the P/S ratio of 86.18% of US stocks.
  • The volatility of Ionis Pharmaceuticals Inc's share price is greater than that of merely 5.86% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ionis Pharmaceuticals Inc are LJPC, ACIA, FGEN, CLLS, and RESN.
  • IONS's SEC filings can be seen here. And to visit Ionis Pharmaceuticals Inc's official web site, go to
IONS Daily Price Range
IONS 52-Week Price Range

IONS Stock Price Chart Technical Analysis Charts

IONS Price/Volume Stats

Current price $62.09 52-week high $73.09
Prev. close $60.44 52-week low $39.32
Day low $60.37 Volume 807,600
Day high $62.16 Avg. volume 926,744
50-day MA $57.31 Dividend yield N/A
200-day MA $57.20 Market Cap 8.65B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ionis Pharmaceuticals Inc. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Ionis Pharmaceuticals Inc ended up being:

  • The compound growth rate in the free cash flow of Ionis Pharmaceuticals Inc over the past 4.76 years is 0.18%; that's better than 57.81% of cash flow producing equities in the Healthcare sector, where it is classified.
  • 91% of the company's capital comes from equity, which is greater than 79.66% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately just 20.3% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See DXCM, LCI, ENTA, GTS, and ZBH.

IONS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

IONS Latest Social Stream

Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Akcea Announces Appointment of New Chief Medical Officer

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C), will serve as an advisor to the company to ensure a smooth transition.

Yahoo | July 9, 2020

Ionis Pharmaceuticals to hold neurology franchise webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise. The approximately 90-minute webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; C. Frank Bennett, Ph.D., chief scientific officer and franchise leader for neurology; Holly Kordasiewicz, Ph.D., vice president, neurology research; and Frank Rigo, Ph.D., vice president, functional genomics and drug discovery. The agenda for the webcast will be as follows:

Yahoo | July 7, 2020

Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow

The following slide deck was published by Ionis Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | June 23, 2020

Ionis Pharmaceuticals, Inc. (IONS) Management Presents at BMO 2020 Prescriptions for Success Healthcare Conference Transcript

Ionis Pharmaceuticals, Inc. (IONS) BMO 2020 Prescriptions for Success Healthcare Conference June 23, 2020, 02:00 PM ET Company Participants Eric Swayze - SVP of Research Wade Walke - IR Conference Call Participants Do Kim - BMO Capital Markets Presentation Do Kim Good morning. My name is Do Kim. I'm one...

SA Transcripts on Seeking Alpha | June 23, 2020

Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive officer, and Kyle Jenne, chief commercial officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference, which is being held virtually, on Tuesday, June 23, 2020 at 3:30 p.m. ET.

Yahoo | June 17, 2020

Read More 'IONS' Stories Here

IONS Price Returns

1-mo 6.37%
3-mo 17.66%
6-mo 0.05%
1-year -5.24%
3-year 20.33%
5-year 12.24%
YTD 2.78%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%
2015 0.31%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9828 seconds.